Journal of Clinical Oncology
Articles in this Issue
Evidence in real-world settings for multiple primary malignancies in prostate cancer: Comparison with single primary prostate cancers.
e23282 Background: With an ageing population and the improvement in prostate cancer survival, the diagnosis of Multiple Primary Malignancies (MPMs) involv...
The combination of PD-1 inhibitor with chemotherapy ± salvage chemoradiotherapy for local primary-recurrence esophageal squamous cell carcinoma after definitive chemoradiotherapy: A prospective, multicenter, single-arm clinical study (ESO-Nanjing12).
e16035 Background: The efficacy of programmed death receptor 1(PD-1) inhibitors combined with chemotherapy for advanced and metastatic ESCC has been recog...
A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors.
TPS2685 Background: CLDN6 is an oncofetal protein expressed at high levels in many solid tumors while expressed at very low levels in adult normal tissues...
Assessment of cell-free DNA (cfDNA) as a biomarker in pancreatico-biliary malignancies: A longitudinal observational cohort study.
e16480 Background: Globally, cfDNA and circulating tumor DNA (ct-DNA) are gaining recognition in Pancreaticobiliary malignancies for prognostic evaluation...
Effect of extrachromosomal DNA (ecDNA) on <i>MYCN</i> amplified neuroblastoma and patient outcomes.
3090 Background: Recurrent cytogenetic abnormalities represent candidate therapeutic targets for children with neuroblastoma (NB). MYCN...
Incidence, factors enabling to predict and management of hypocalcemia following total thyroidectomy for thyroid cancer: A prospective observational study.
e18127 Background: Hypocalcemia (transient) is the most common complication following total thyroidectomy. It may or may not be accompanied by hypoparathy...
Real-world treatment patterns and outcomes in HER2-positive metastatic breast cancer patients with brain metastases.
e13022 Background: The treatment paradigm for HER2+ metastatic breast cancer (MBC) patients with brain metastases (BM) has shifted from local therapies to...
Prediction of sotorasib response duration and identification of clinically actionable resistance mechanisms using an RNA- and machine learning–based patient classifier.
e13614 Background: KRAS mutations are the most common oncogenic drivers in cancer. While first-generation KRAS inhibitors (KRASi) represent a therapeutic...
Adequacy of immune checkpoint inhibitor-associated thyroid function monitoring following therapy.
12116 Background: Immune checkpoint inhibitor (ICI)-induced thyroid dysfunction is the most common endocrine immune-related adverse event. While ICI-induc...
Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study.
2019 Background: Primary central nervous system lymphoma (PCNSL) is a rare, aggressive form of non-Hodgkin lymphoma localized to the brain, cerebrospinal...
Utility of HPV test with urine cytology in bladder cancer screening.
e16577 Background: Bladder cancer (BC) is a common malignancy with high morbidity and mortality rates, and early detection plays a crucial role in improvi...
Comparison of IMWG and PANGEA risk models predicting MGUS to multiple myeloma progression in a safety net hospital.
e19534 Background: The Personalised progression prediction model (PANGEA) and International Myeloma Working Group (IMWG) models offer different approaches...
Thymidine kinase activity as a prognostic tool in blood samples of primary ovarian cancer patients.
e17602 Background: Prognostic markers in serous ovarian cancer (OC) include CA125 serum level, FIGO-stage, lymph node-status, postoperative residual tumor...
Intravesical sacituzumab tirumotecan in participants with intermediate-risk non–muscle-invasive bladder cancer: The phase 1/2 TroFuse-027 study.
TPS4627 Background: Standard treatment for patients with intermediate-risk (IR) non–muscle-invasive bladder cancer (NMIBC) is transurethral resection of b...
Enhancing precision oncology for Haitian breast cancer patients through deep learning-enabled computational pathology tools.
1080 Background: While early-stage breast cancer is often curable in high-resource settings, mortality-to-incidence ratios remain unacceptably high for wo...
Genetic predictors of 16,000 multi-omic traits and associations with breast cancer survival outcomes in the Pathways Study.
10545 Background: Polygenic scores (PGS) enable the computation of a genetic predictor for any trait where a well-developed algorithm is available. This i...
Neoadjuvant tislelizumab combined with disitamab vedotin (RC48) for patients with Her-2 expressing upper tract urothelial carcinoma: A pilot study.
e16588 Background: Cisplatin-based chemotherapy is regarded as the standard treatment for the neoadjuvant therapy of upper urinary tract urothelial carcin...
Burkitt lymphoma incidence in relation to HIV prevalence in United States: A regression analysis.
e19069 Background: Burkitt lymphoma (BL) is a rare and aggressive malignancy that is hypothesized to have a potential association with HIV due to the immu...
Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.
TPS8666 Background: Oncogenic ALK gene fusions are detected in ~5% of advanced non-small cell lung cancer (NSCLC) cases. Among the...
Retrospective review of relapse after allogeneic stem cell transplant for myeloid malignancy.
e18548 Background: Relapsed disease after allogeneic stem cell transplant (alloHSCT) is the leading cause of post-transplant death. We retrospectively cha...
Efficacy and safety of second-line therapy by envafolimab combined with anlotinib and S-1 in pancreatic cancer patients: A single-arm, phase II clinical trial.
e16385 Background: Pancreatic adenocarcinoma carries a grim prognosis, and there are few recognized effective second line and later line treatment strateg...
Delineation of immunotherapeutic predictive versus prognostic transcriptional programs to identify SLC22A5-centric carnitine metabolism-driven resistance to anti-PD-L1 treatment in advanced non–small-cell lung cancer.
2623 Background: Prognostic factors indicate the natural course of a disease regardless of treatment, whereas predictive factors determine the likelihood...
SmarT cell combined with PD-1 blockade and SOX as first-line treatment for patients with advanced gastric/gastroesophageal junction adenocarcinoma.
e16082 Background: Although PD-1 blokade plus chemotherapy has achieved a preferable response rate for advanced advanced gastric/gastroesophageal junction...
Introducing a capacity building model to improve cancer research in MENA.
9023 Background: The Middle East and North Africa (MENA) region faces a rising cancer burden, straining healthcare systems. The scarcity of cancer researc...
Imaging and biomarker factors for predicting durable responses to 177Lu-PSMA therapy in metastatic castration resistant prostate cancer (mCRPC).
e17070 Background: 177Lu-PSMA radioligand therapy (RLT) has shown promising response rates and improved survival in metastatic castration-resistant prosta...